Coherus Oncology Statistics
Total Valuation
CHRS has a market cap or net worth of $236.00 million. The enterprise value is $129.50 million.
Important Dates
The last earnings date was Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CHRS has 154.25 million shares outstanding. The number of shares has increased by 6.02% in one year.
| Current Share Class | 154.25M |
| Shares Outstanding | 154.25M |
| Shares Change (YoY) | +6.02% |
| Shares Change (QoQ) | +13.32% |
| Owned by Insiders (%) | 14.06% |
| Owned by Institutions (%) | 42.95% |
| Float | 132.53M |
Valuation Ratios
The trailing PE ratio is 1.01.
| PE Ratio | 1.01 |
| Forward PE | n/a |
| PS Ratio | 5.17 |
| Forward PS | 2.79 |
| PB Ratio | 3.08 |
| P/TBV Ratio | 7.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 0.70 |
| EV / Sales | 2.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.69.
| Current Ratio | 1.56 |
| Quick Ratio | 1.43 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -32.80% |
| Return on Invested Capital (ROIC) | -83.90% |
| Return on Capital Employed (ROCE) | -125.03% |
| Weighted Average Cost of Capital (WACC) | 10.45% |
| Revenue Per Employee | $323,331 |
| Profits Per Employee | $1.28M |
| Employee Count | 145 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 3.59 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +104.99% in the last 52 weeks. The beta is 1.02, so CHRS's price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | +104.99% |
| 50-Day Moving Average | 1.74 |
| 200-Day Moving Average | 1.56 |
| Relative Strength Index (RSI) | 39.23 |
| Average Volume (20 Days) | 1,303,685 |
Short Selling Information
The latest short interest is 27.82 million, so 18.03% of the outstanding shares have been sold short.
| Short Interest | 27.82M |
| Short Previous Month | 27.97M |
| Short % of Shares Out | 18.03% |
| Short % of Float | 20.99% |
| Short Ratio (days to cover) | 29.32 |
Income Statement
In the last 12 months, CHRS had revenue of $46.88 million and earned $186.27 million in profits. Earnings per share was $1.52.
| Revenue | 46.88M |
| Gross Profit | 31.91M |
| Operating Income | -167.15M |
| Pretax Income | -172.66M |
| Net Income | 186.27M |
| EBITDA | -163.39M |
| EBIT | -167.15M |
| Earnings Per Share (EPS) | $1.52 |
Full Income StatementBalance Sheet
The company has $167.05 million in cash and $54.37 million in debt, with a net cash position of $112.68 million or $0.73 per share.
| Cash & Cash Equivalents | 167.05M |
| Total Debt | 54.37M |
| Net Cash | 112.68M |
| Net Cash Per Share | $0.73 |
| Equity (Book Value) | 78.62M |
| Book Value Per Share | 0.51 |
| Working Capital | 73.70M |
Full Balance SheetCash Flow
| Operating Cash Flow | -170.57M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 3.76M |
| Net Borrowing | -233.19M |
| Free Cash Flow | -170.57M |
| FCF Per Share | -$1.11 |
Full Cash Flow StatementMargins
Gross margin is 68.06%, with operating and profit margins of -356.53% and 397.30%.
| Gross Margin | 68.06% |
| Operating Margin | -356.53% |
| Pretax Margin | -368.28% |
| Profit Margin | 397.30% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CHRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.02% |
| Shareholder Yield | -6.02% |
| Earnings Yield | 76.91% |
| FCF Yield | -70.43% |
Analyst Forecast
The average price target for CHRS is $7.80, which is 409.80% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.80 |
| Price Target Difference | 409.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 45.65% |
| EPS Growth Forecast (5Y) | 2.32% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHRS has an Altman Z-Score of -8.53 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.53 |
| Piotroski F-Score | 4 |
